CPA
GLUE icon

Capital Performance Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Capital Performance Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-29
Closed -$154 – 1153
2024
Q3 		$154 Buy
+29
New +$146 ﹤0.01% 2615

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Performance Advisors's GLUE Position: Q4 2024 in Review

Capital Performance Advisors sold out of Monte Rosa Therapeutics (GLUE) in Q4 2024, closing a stake of 29 shares — an estimated $154 sold.

Capital Performance Advisors first reported a position in GLUE in Q3 2024 and held it in 1 quarter. The position peaked at $154 in Q3 2024. 104 funds tracked by Wall St. Rank hold GLUE as of Q4 2024.

  • Capital Performance Advisors reported no remaining Monte Rosa Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 29 Monte Rosa Therapeutics shares in Q4 2024, an estimated $154.
  • Capital Performance Advisors first reported a position in Monte Rosa Therapeutics in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Monte Rosa Therapeutics position peaked at $154 in Q3 2024.
  • 104 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.